{
    "clinical_study": {
        "@rank": "141114", 
        "acronym": "ESTABOMA", 
        "arm_group": [
            {
                "arm_group_label": "Transplantation of BMMCs", 
                "arm_group_type": "Experimental", 
                "description": "Autologous BMCs  aspiration and  transplantation of these cells"
            }, 
            {
                "arm_group_label": "Transplantation of CD 133+ cells", 
                "arm_group_type": "Experimental", 
                "description": "Autologous  CD 133+ BMCs aspiration and  transplantation of CD 133+ cells"
            }, 
            {
                "arm_group_label": "stenting of IRA", 
                "arm_group_type": "Active Comparator", 
                "description": "The only stenting of IRA"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the hypothesis that the intracoronary transplantation\n      of autologous mononuclear and CD 133 + bone marrow cells will improve left ventricular\n      contractile function and will reduce the combined end points after the primary STEMI\n      (mortality, recurrent myocardial infarction, angina, heart failure, stroke)."
        }, 
        "brief_title": "The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vascular Diseases", 
            "Cardiovascular Diseases", 
            "Acute Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Infarction", 
                "Myocardial Infarction", 
                "Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study was randomized, opened, controlled. 85 patients  with the first STEMI were\n      enrolled. Patients were divided to three groups. On admission all patients were received\n      thrombolytic therapy by 1,5 million U streptokinase. Transplantation of autologous\n      mononuclear bone marrow cells (BMMCs) and  \u0430utologous CD133 + cells by balloon catheter\n      placed into infarct-related artery (IRA) was performed at once after stent implantation  in\n      28 patients  patients (1st group) and in 10 patients (2nd group) on the 7-21  days of STEMI.\n      Another 47 patients (3nd group) undergo only stent implantation into IRA the same day of\n      STEMI.\n\n      Autologous BMMCs were obtained from bone marrow aspirate by gradient centrifugation.\n      Echocardiography, Holter monitoring were performed. Plasma concentration  of the\n      pro-inflammatory and anti-inflammatory cytokines (IL1, 6,8,10), of the growth factors (stem\n      cell factor - SCF, vascular endothelial growth factor - VEGF, hepatocyte growth factor -\n      HGF, fibroblast growth factor - FGF, insulin-like growth factor - IGF), the number of\n      circulating CD34 +38-, CD133 +, \u0421D117 +, CD90 +34- stem cells  were determined in these\n      patients in the acute and sub-acute myocardial infarction period.\n\n      It is going 7 years after the beginning of planned to evaluate left ventricular function of\n      these patients, incidence of cardiovascular end points (death, recurrent myocardial\n      infarction, angina, heart failure, stroke) and their combinations, to evaluate the safety of\n      transplantation of autologous BMCs (formation of intra-myocardial tumor or neoplastic\n      processes of other sites) after 7 years from the beginning of study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years and to 75 Years\n\n          -  Informed consent\n\n          -  First STEMI\n\n          -  Term admission to an intensive care unit  in the first 24 hours of onset\n\n          -  Time reperfusion of the IRA is not earlier than 4 hours after the initial onset of\n             acute transmural myocardial infarction\n\n        Exclusion Criteria:\n\n          -  Atrial fibrillation, a permanent form Valvular heart disease\n\n          -  Severe comorbidity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "85", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748383", 
            "org_study_id": "99"
        }, 
        "intervention": [
            {
                "arm_group_label": "Transplantation of BMMCs", 
                "description": "The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93\u00b143 million transplantation by balloon catheter performed  into IRA at once after stent implantation.", 
                "intervention_name": "Transplantation of BMMCs", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Transplantation of CD 133+ cells", 
                "description": "The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous  CD 133+ BMCs in the number 5,7 (0,45;9,0) million   transplantation by balloon catheter performed  into IRA at once after stent implantation.", 
                "intervention_name": "Transplantation of CD 133+ cells", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "stenting of IRA", 
                "description": "The only stent implantation", 
                "intervention_name": "stenting of IRA", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bone marrow cells", 
            "Acute myocardial infarction", 
            "Transplantation of autologous mononuclear", 
            "Transplantation of autologous CD133 + cells"
        ], 
        "lastchanged_date": "December 13, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tomsk", 
                    "country": "Russian Federation", 
                    "zip": "634012"
                }, 
                "name": "Scientific and Research Institution of Cardiology of Siberian Department of RAMS"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "3", 
        "official_title": "Autologous Mononuclear and Cluster of Differentiation 133+ (CD 133+) Bone Marrow Cells, Growth Factors and Cytokines in the Remodeling of the Heart in Patients During and in the Late Periods After STEMI.", 
        "overall_official": {
            "affiliation": "Scientific and Research Institution of Cardiology of Siberian Department of RAMS", 
            "last_name": "Vyacheslav Ryabov, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Left ventricular ejection fraction  (Echo)", 
            "safety_issue": "No", 
            "time_frame": "for an average of 7 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748383"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Russian Academy of Medical Sciences", 
            "investigator_full_name": "Vyacheslav Ryabov", 
            "investigator_title": "Leading researcher of Emergency Cardiology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "incidence of cardiovascular death", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "incidence of the recurrent myocardial infarction", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "incidence of the angina", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "incidence of the heart failure", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "incidence of the stroke", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "incidence of the combined endpoint", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "incidence and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }
        ], 
        "source": "Russian Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Russian Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}